Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenalisib and Pembrolizumab in Relapsed/Refractory cHL
NCT03471351Phase 1Terminated
- Sponsor
- Rhizen Pharmaceuticals AG
- Start
- Jul 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tenalisib in classical Hodgkin lymphoma (cHL), sponsored by Rhizen Pharmaceuticals AG. Primary endpoint: Maximum tolerated dose at 21 days. Started Jul 2018; status: terminated.
02
Drugs
tenalisib
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT03471351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03471351.